These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29973234)

  • 1. Genetic characterisation of molecular targets in carcinoma of unknown primary.
    Clynick B; Dessauvagie B; Sterrett G; Harvey NT; Allcock RJN; Saunders C; Erber W; Meehan K
    J Transl Med; 2018 Jul; 16(1):185. PubMed ID: 29973234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
    Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
    Löffler H; Pfarr N; Kriegsmann M; Endris V; Hielscher T; Lohneis P; Folprecht G; Stenzinger A; Dietel M; Weichert W; Krämer A
    Oncotarget; 2016 Jul; 7(28):44322-44329. PubMed ID: 27322425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP).
    Es HA; Mahdizadeh H; Asl AAH; Totonchi M
    Sci Rep; 2021 Jul; 11(1):15112. PubMed ID: 34302033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
    Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
    Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
    Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
    J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.
    Kato S; Krishnamurthy N; Banks KC; De P; Williams K; Williams C; Leyland-Jones B; Lippman SM; Lanman RB; Kurzrock R
    Cancer Res; 2017 Aug; 77(16):4238-4246. PubMed ID: 28642281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
    Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
    JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.
    Varghese AM; Arora A; Capanu M; Camacho N; Won HH; Zehir A; Gao J; Chakravarty D; Schultz N; Klimstra DS; Ladanyi M; Hyman DM; Solit DB; Berger MF; Saltz LB
    Ann Oncol; 2017 Dec; 28(12):3015-3021. PubMed ID: 29045506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.
    Boscolo Bielo L; Belli C; Crimini E; Repetto M; Ascione L; Pellizzari G; Santoro C; Fuorivia V; Barberis M; Fusco N; Rocco EG; Curigliano G
    Oncologist; 2024 Jun; 29(6):504-510. PubMed ID: 38520742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic characterisation of sarcomatoid carcinomas reveals multiple novel actionable mutations and identifies
    Ding Y; Shao Y; Na C; Yin JC; Hua H; Tao R; Jiang Y; Hu R; He X; Miao C; Zhu D; Zhang Z
    J Med Genet; 2022 Jan; 59(1):10-17. PubMed ID: 33115932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome.
    Bochtler T; Endris V; Leichsenring J; Reiling A; Neumann O; Volckmar AL; Kirchner M; Allgäuer M; Schirmacher P; Krämer A; Stenzinger A
    Int J Cancer; 2019 Dec; 145(11):2963-2973. PubMed ID: 30963573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
    Westphalen CB; Federer-Gsponer J; Pauli C; Karapetyan AR; Chalabi N; Durán-Pacheco G; Beringer A; Bochtler T; Cook N; Höglander E; Jin DX; Losa F; Mileshkin L; Moch H; Ross JS; Sokol ES; Tothill RW; Krämer A
    ESMO Open; 2023 Dec; 8(6):102035. PubMed ID: 37922692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary.
    Bochtler T; Wohlfromm T; Hielscher T; Stichel D; Pouyiourou M; Kraft B; Neumann O; Endris V; von Deimling A; Stenzinger A; Krämer A
    Genes Chromosomes Cancer; 2022 Sep; 61(9):551-560. PubMed ID: 35430765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and management of metastatic neoplasms with unknown primary.
    Bochtler T; Löffler H; Krämer A
    Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.
    Rassy E; Boussios S; Pavlidis N
    Eur J Clin Invest; 2021 Sep; 51(9):e13583. PubMed ID: 33970501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
    Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
    Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling.
    Binder C; Matthes KL; Korol D; Rohrmann S; Moch H
    Cancer Med; 2018 Sep; 7(9):4814-4824. PubMed ID: 30019510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.